ESR1 and breast cancer: Furthermore, we assessed a previously published BBD signature that was associated with risk of triple negative BC for association in our dataset [15]; we did not observe presence of the signature in our sample, overall, or within ER+, ER−, or triple negative cases (p > 0.05, data not shown).